Abstract Library

#1895 Prospective Study on the Impact of a Multi-Institutional NET-Specific Multidisciplinary Tumor Board on Individual Treatment Plans

Introduction: A multi-institutional health network (nine hospitals) was set up in the Belgian Antwerp-Waasland region for the multidisciplinary care of gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients, called “NETwerk”. Local multidisciplinary teams refer all GEP-NET patients to be discussed among specialists, experienced in NET diagnostics and treatment, at a NET specific multidisciplinary tumorboard (MDT).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Peeters M

Authors: Lybaert W, Vandamme T, Simoens M, Dero I, Demey W,

Keywords: care networks, quality,

#1543 Is True Non-Secretion of Chromogranin A an Unfavorable Prognostic Factor in Patients with ENETs TNM Stage IV Gastroenteropancreatic Neuroendocrine Tumors?

Introduction: Chromogranin A (CgA) is the best available serum marker for the work-up of gastroenteropancreatic NETs (GEP-NETs) and correlates with tumor volume & biological activity. During diagnosis & follow-up we found patients with elevated CgA levels and patients without elevated CgA levels (=‘true non-secretors’). We postulated that lack of secretion is a sign of dedifferentiation with a poorer prognosis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kamp K

Authors: Kamp K, Adrichem van R, Vandamme T, Peeters M, Feelders R,

Keywords: GEP-NET, CgA, prognosis,

#490 Effect of Open-Label Everolimus After Disease Progression in Patients with Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis

Introduction: In the RADIANT-2 study (NCT00412061), Everolimus + Octreotide LAR (E+O) resulted in a clinically meaningful increase in median progression-free survival (PFS; by adjudicated central review) of 5.1 months v. placebo + Octreotide LAR (P+O) in patients with advanced NET with a history of carcinoid syndrome. Investigator-assessed PFS was 12.0 months for E+O compared with 8.6 months for P+O, respectively. On radiologically confirmed disease progression, P+O patients could cross over to open-label E+O.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hörsch D, Luppi G, Jehl V, Peeters M, Hainsworth J,

Keywords: Everolimus, Octreotide LAR, somatostatin analog, mTOR,

#334 Everolimus + Octreotide LAR v. Placebo + Octreotide LAR in Patients With Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)

Introduction: Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase 2 studies.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Pavel M, Peeters M, Höersch D, Van Cutsem E, Öberg K,

Keywords: mTOR, everolimus, octreotide LAR, neuroendocrine tumor,